Imugene (Australia) Performance
| IMU Stock | 0.04 0 5.26% |
The company retains a Market Volatility (i.e., Beta) of 0.0744, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Imugene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Imugene is expected to be smaller as well. At this point, Imugene has a negative expected return of -0.61%. Please make sure to check out Imugene's skewness, accumulation distribution, and the relationship between the potential upside and kurtosis , to decide if Imugene performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Imugene has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:7.5 | Last Split Date 2002-11-12 |
1 | Imugene Ltd. announced that it has received AUD 2.60 million in funding. - Marketscreener.com | 10/04/2024 |
2 | ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - MSN | 11/21/2024 |
| Begin Period Cash Flow | 153.2 M |
Imugene |
Imugene Relative Risk vs. Return Landscape
If you would invest 6.20 in Imugene on August 30, 2024 and sell it today you would lose (2.20) from holding Imugene or give up 35.48% of portfolio value over 90 days. Imugene is producing return of less than zero assuming 3.9244% volatility of returns over the 90 days investment horizon. Simply put, 34% of all stocks have less volatile historical return distribution than Imugene, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Imugene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Imugene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Imugene, and traders can use it to determine the average amount a Imugene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1545
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMU |
Estimated Market Risk
| 3.92 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.61 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Imugene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imugene by adding Imugene to a well-diversified portfolio.
Imugene Fundamentals Growth
Imugene Stock prices reflect investors' perceptions of the future prospects and financial health of Imugene, and Imugene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imugene Stock performance.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 22.86 % | ||||
| Current Valuation | 195.99 M | ||||
| Shares Outstanding | 7.57 B | ||||
| Price To Book | 2.43 X | ||||
| Price To Sales | 60.90 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | 11.78 M | ||||
| EBITDA | (147.98 M) | ||||
| Net Income | (149.68 M) | ||||
| Cash And Equivalents | 49.54 M | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (97.32 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Total Asset | 151.4 M | ||||
| Retained Earnings | (289.83 M) | ||||
About Imugene Performance
Assessing Imugene's fundamental ratios provides investors with valuable insights into Imugene's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Imugene is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Imugene is entity of Australia. It is traded as Stock on AU exchange.Things to note about Imugene performance evaluation
Checking the ongoing alerts about Imugene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Imugene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Imugene generated a negative expected return over the last 90 days | |
| Imugene has some characteristics of a very speculative penny stock | |
| Imugene has high historical volatility and very poor performance | |
| Imugene has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.97 M. Net Loss for the year was (149.68 M) with profit before overhead, payroll, taxes, and interest of 11.78 M. | |
| Imugene has accumulated about 49.54 M in cash with (97.32 M) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - MSN |
- Analyzing Imugene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imugene's stock is overvalued or undervalued compared to its peers.
- Examining Imugene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Imugene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imugene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Imugene's stock. These opinions can provide insight into Imugene's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.